Polycystic ovary syndrome - Pipeline Insight, 2022

DelveInsight's , "Polycystic ovary syndrome - Pipeline Insight, 2022," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Polycystic ovary syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

• Global coverage

Polycystic ovary syndrome Understanding

Polycystic ovary syndrome: Overview

Polycystic ovary syndrome (PCOS) is a condition that affects a woman's hormone levels. Polycystic ovary syndrome (PCOS) is a health problem that affects 1 in 10 women of childbearing age. Women with PCOS have a hormonal imbalance and metabolism problems that may affect their overall health and appearance. PCOS is also a common and treatable cause of infertility. Some of the symptoms of PCOS include: Irregular menstrual cycle, too much hair on the face, chin, or parts of the body where men usually have hair, Acne on the face, chest, and upper back, Weight gain or difficulty losing weight, Darkening of skin, particularly along neck creases, in the groin, and underneath breasts. There is no single test to diagnose PCOS. To help diagnose PCOS and rule out other causes of symptoms, medical history and physical exam is evaluated and different tests are performed. There is no cure for PCOS, but the symptoms of PCOS can be managed.

"Polycystic ovary syndrome - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Polycystic ovary syndrome pipeline landscape is provided which includes the disease overview and Polycystic ovary syndrome treatment guidelines. The assessment part of the report embraces, in depth Polycystic ovary syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Polycystic ovary syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights:

The companies and academics are working to assess challenges and seek opportunities that could influence Polycystic ovary syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Polycystic ovary syndrome.

Polycystic ovary syndrome Emerging Drugs Chapters

This segment of the Polycystic ovary syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Polycystic ovary syndrome Emerging Drugs

Tildacerfont: Spruce Biosciences

Tildacerfont is a CRF1 receptor antagonist designed to potentially offer markedly improved disease control and reduced steroid burden in patients with classic congenital adrenal hyperplasia (CAH) and other diseases characterized by elevated levels of adrenocorticotropic hormone (ACTH). Tildacerfont binds to CRF1 receptors on the pituitary gland, inhibiting excessive production of ACTH, and ultimately limiting the production of adrenal androgens such as androstenedione, a precursor to testosterone.Tildacerfont is in late-stage trials for the treatment of adult classic CAH, with a Phase 2 trial planned in pediatric CAH. Tildacerfont may also benefit patients with other disorders in which elevated levels of or hyperresponsiveness to adrenocorticotropic hormone (ACTH) occur, including a rare form of polycystic ovary syndrome (PCOS).The drug is currently in Phase II stage of development for the treatment of patients with polycystic ovary syndrome.

Elagolix: Abbvie/ Neurocrine Biosciences

Elagolix (ABT-620) is an oral gonadotropin-releasing hormone antagonist being studied for the treatment of endometriosis, uterine fibroids and PCOS. Elagolix is a highly potent GnRH receptor antagonist that inhibits endogenous GnRH signaling by binding competitively to GnRH receptors in the anterior pituitary gland. The drug is currently in Phase II stage of development for the treatment of patients with polycystic ovary syndrome.

Further product details are provided in the report:

Polycystic ovary syndrome: Therapeutic Assessment

This segment of the report provides insights about the different Polycystic ovary syndrome drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Polycystic ovary syndrome

There are approx. 8+ key companies which are developing the therapies for Polycystic ovary syndrome. The companies which have their Polycystic ovary syndrome drug candidates in the most advanced stage, i.e. Phase II include, Spruce Biosciences.

Phases

DelveInsight's report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Polycystic ovary syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as:

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Polycystic ovary syndrome: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Polycystic ovary syndrome therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Polycystic ovary syndrome drugs.

Polycystic ovary syndrome Report Insights

• Polycystic ovary syndrome Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Polycystic ovary syndrome Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Polycystic ovary syndrome drugs?

• How many Polycystic ovary syndrome drugs are developed by each company?

• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Polycystic ovary syndrome?

• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Polycystic ovary syndrome therapeutics?

• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

• What are the clinical studies going on for Polycystic ovary syndrome and their status?

• What are the key designations that have been granted to the emerging drugs?

Key Players

• AbbVie
• Spruce Biosciences
• Zydus Therapeutics Inc.

Key Products

• Elagolix
• Tildacerfont
• Saroglitazar Magnesium